Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Kansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Kansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Kansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Joseph Moore (NPI 1750777959)

Field	Value
Entity Type	Individual
Organization	Joseph Moore
Address	3243 E Murdock St Ste 300
City	Wichita
State	KS
ZIP	67208
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	April 14, 2015

Payer Source	Total Paid
Medicare	$3.6M
Medicaid	$0

Key Findings

This provider is effectively single‑payer: lifetime Medicare revenue totals $3.6M while there is no Medicaid billing on file, so the provider’s commercial/Medicaid exposure is not represented in these records and Medicare drives the entire observed revenue footprint. Analysts should treat the practice as Medicare-centric when modeling payer mix or utilization patterns.

Revenue is highly concentrated in a small set of infusion drug codes: the precomputed top three Medicare codes account for 47.0% of total Medicare revenue, led by J9271 at $920.2K (27.7%), followed by J9299 at $354.7K (10.7%) and J9173 at $285.1K (8.6%). This concentration implies financial dependence on high-cost oncology biologics rather than office‑visit billing.

The CPT/HCPCS mix signals a specialty infusion oncology and hematology practice: major contributors include immunotherapy/monoclonal antibody administrations such as J9271 (pembrolizumab), J9299 (nivolumab) and J9173 (durvalumab), supported by chemotherapy administration 96413 and imaging 78815. Supportive-care and biologic agents (for example Q5107, Q5115, Q5108, J2796, and J1568) appear throughout the top codes, consistent with a practice that delivers complex infusions and oncology supportive treatments on site.

Competitive standing against national Medicare peers is mixed: J9271 generates $920.2K and ranks #328 of 1841 providers nationally (82th percentile; typical, unremarkable volume for this code), indicating pembrolizumab use is in line with many peers rather than dominant. J9299 ranks #252 of 505 (50th percentile; typical, unremarkable volume for this code), so nivolumab volume is also broadly typical among reporting providers.

Several codes are statistically notable and suggest above‑average operational intensity in specific areas: chemotherapy administration 96413 ranks #163 of 7514 providers nationally (98th percentile; notably above typical national volume for this code), J0185 ranks #23 of 819 (97th percentile; notably above typical national volume for this code), and 96367 ranks #117 of 4032 (97th percentile; notably above typical national volume for this code). Additionally, the new‑patient E/M code 99205 is an extreme outlier (ranks #620 of 66257 providers nationally, 99th percentile), indicating an unusually high volume of high‑complexity new patient visits relative to national peers. Together these outlier positions point to a clinic that handles a disproportionate share of high‑acuity oncology administrations and initial consultations.

There are areas of lower national presence that suggest selective use of certain agents: J9145 (daratumumab, 10 mg) produced $217.1K but ranks #12 of 14 providers nationally (15th percentile; typical, unremarkable volume for this code) and J2796 (romiplostim) ranks #19 of 20 (5th percentile; typical, unremarkable volume for this code). These lower percentiles indicate the provider participates in those specific therapies at a much smaller scale compared with the subset of peers who bill them.

Operational revenue mix favors infused drug revenue over office visit billing: the single largest line item is J9271 at $920.2K (27.7% of Medicare revenue) while the top E/M codes produce comparatively minor Medicare dollars (99214 $61.4K, 1.8%; 99213 $28.7K, 0.9%). This suggests clinic throughput and revenue are driven predominantly by drug administration and infusion sessions rather than by routine face‑to‑face outpatient evaluation and management.

The provider has an established Medicare presence with an NPI enumerated on 2015-04-14 (~11 years ago), which supports interpreting these utilization patterns as the output of a multi‑year, stable practice rather than a short‑term or newly formed operation. Analysts can reasonably benchmark current patterns against this roughly decade‑long tenure when assessing growth or contraction trends.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

102 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	21,400	$40	$920.2K
J9299	Injection, nivolumab, 1 mg	14,780	$20	$354.7K
J9173	Injection, durvalumab, 10 mg	4,600	$60	$285.1K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	5,580	$40	$217.6K
J9145	Injection, daratumumab, 10 mg	4,620	$50	$217.1K
J9047	Injection, carfilzomib, 1 mg	5,860	$40	$216.8K
J0897	Injection, denosumab, 1 mg	7,380	$20	$140.2K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	3,390	$30	$115.4K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	2,580	$40	$90.3K
J2796	Injection, romiplostim, 10 micrograms	1,200	$70	$88.8K

Showing 1–10 of 102

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 102 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Kansas Distribution

Joseph Moore — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Kansas

Full comparison — all codes billed, vs. state median

102 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	14	20	28,900	$40	$1.1M
J9299	13	10	24,550	$20	$637.2K
J9145	8	10	6,660	$50	$394.7K
J9144	5	10	6,300	$40	$257.2K
J9173	2	10	3,480	$60	$230.3K
J9047	1	10	5,860	$40	$215.4K
J2796	4	10	2,380	$70	$208.4K
J1568	8	10	3,690	$30	$129K
Q5107	8	10	4,440	$20	$106.5K
Q5115	4	10	2,340	$30	$92.9K

Showing 1–10 of 102

Related Providers

Other providers that share a Tax Identification Number (TIN) with Joseph Moore, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
David Dyer	KS	Ophthalmology Physician	$7.5M	$0
Bassam Mattar	KS	Hematology & Oncology Physician	$7.2M	$0
Dennis Moore	KS	Hematology & Oncology Physician	$6.7M	$0
Pavan Reddy	KS	Hematology & Oncology Physician	$6.7M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Thomas Finley	OK	Ophthalmology Physician	$4.8M	$0
Daniel Feiler	KS	Ophthalmology Physician	$4.8M	$0
Travis Koeneke	KS	Hematology & Oncology Physician	$4.4M	$0
Christopher Dakhil	KS	Hematology & Oncology Physician	$4.4M	$0
Stephen Wiles	MO	Ophthalmology Physician	$4.4M	$0

Nearby Providers

Other providers in the same ZIP code as Joseph Moore, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ascension Medical Group Via Christi, PA	KS	Multi-Specialty Clinic/Center	$0	$21.2M
County Of Sedgwick	KS	Case Manager/Care Coordinator	$0	$15.5M
County Of Sedgwick	KS	Psychiatry Physician	$0	$5.9M
Great Plains Dental Group, LLC	KS	General Practice Dentistry	$0	$5.8M
Mental Health America Of South Central Kansas, Inc.	KS	Community/Behavioral Health Agency	$0	$5.7M
Kidspace Pediatric Dentistry,p.a	KS	Pediatric Dentistry	$0	$4.4M
Cerebral Palsy Research Foundation Of Kansas, Inc	KS	Non-emergency Medical Transport (VAN)	$0	$4.3M
Nassim Nabbout	KS	Hematology & Oncology Physician	$4.2M	$0
Phu Truong	KS	Hematology & Oncology Physician	$4.1M	$0
Grace Home Care, LLC	KS	Home Health Agency	$0	$4M

Joseph Moore — Billing Profile & Reimbursement Data

Sign up for Joseph Moore — Billing Profile & Reimbursement Data policy alerts

Joseph Moore — Billing Profile & Reimbursement Data

Sign up for Joseph Moore — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References